Therapeutic (induced) hypothermia (TH) has been extensively studied as a means to reduce brain injury following global and focal cerebral ischemia, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). Here, we briefly review the clinical and experimental evidence supporting the use of TH in each condition. We emphasize the importance of systematically evaluating treatment parameters, especially the duration of cooling, in each condition. We contend that TH provides considerable protection after global and focal cerebral ischemia, especially when cooling is prolonged (e.g., >24 h). However, there is presently insufficient evidence to support the clinical use of TH for ICH and SAH. In any case, further animal work is needed to develop optimized protocols for treating cardiac arrest (global ischemia), and to maximize the likelihood of successful clinical translation in focal cerebral ischemia.
Introduction
N o other cytoprotective (neuroprotective) treatment has been so extensively studied as therapeutic hypothermia (TH). Indeed, there are hundreds of animal studies, dozens of clinical trials, numerous comprehensive reviews (Colbourne et al., 1997; Dietrich et al., 1996; Zhao et al., 2007) , and a recent meta-analysis (van der Worp et al., 2007) . Our purpose here is not to completely review this literature, but to focus on a few issues of central importance to treatment success, such as the duration of TH. We further limit the scope of this review to ischemic and hemorrhagic brain injury in adults, and mostly to work done in animal stroke and cardiac arrest models. The goals of these pre-clinical studies of TH, which have mostly been done in rodents, are to (1) determine whether TH improves outcome for each insult type, (2) clarify the conditions under which protection is found (e.g., intervention delay), (3) optimize treatment parameters, (4) identify possible side effects (e.g., re-warming complications), and (5) determine how TH works so that it may be augmented or replaced with safer and easier-to-administer treatments. This review deals largely with goals 1-3.
Despite over five decades of research, which has intensified considerably over the past 20 years, we have had only limited clinical success with cooling patients for acute brain injury. In 2002, randomized trials showed that TH lessened mortality and improved functional outlook in out-of-hospital cardiac arrest (global ischemia) patients (Bernard et al., 2002 ; The Hypothermia After Cardiac Arrest Study Group, 2002) . Positive results were subsequently obtained in neonates experiencing hypoxic-ischemic encephalopathy (Gluckman et al., 2005; Shankaran et al., 2005) . Conversely, a large clinical trial for traumatic brain injury (TBI) was negative (Clifton et al., 2001) . Finally, clinical findings on using TH to treat focal cerebral ischemia, intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) are encouraging, but far from definitive (Feng et al., 2002; Gasser et al., 2003; Kammersgaard et al., 2000; Milhaud et al., 2005; Schwab et al., 1998 Schwab et al., , 2001 .
Given the recent clinical successes, some are tempted to treat ischemic and hemorrhagic stroke patients with comparable TH protocols. However, this may be premature and catastrophic. Despite TH being a broad-spectrum cytoprotectant, it does not equally protect against TBI, ischemia, and hemorrhage. This is not surprising given the many differences among these insults (e.g., pathophysiology, patient characteristics). Furthermore, side effects of TH protocols and their consequences will vary with each insult. Thus, it makes more sense to further investigate the efficacy of TH using animal models of each stroke type so as to optimize TH protocols for the condition (i.e., ischemia vs. ICH vs. SAH) and situation (e.g., intervention delay). This will not only increase the likelihood of success in areas that TH has yet to be clinically proven to work (e.g., focal ischemia), but it will also help improve upon existing clinical protocols (i.e., cardiac arrest).
Animal neuroprotection studies have been widely criticized for failing to generate translational successes. Thus, in an effort to improve this process, reviewers have identified many important study design problems and methodological weaknesses (Stroke Therapy Academic Industry Roundtable [STAIR], 1999) . Of these, we discuss a few that are especially germane to the current discussion on TH. First, it is not sufficient to rely solely upon histological endpoints in animal studies because reductions in cell death (e.g., infarct volume) may not necessarily improve functional outcome. Conversely, improved recovery can occur independently of neuroprotection. Thus, both histological and behavioral endpoints should be used. We note too that simple measures of recovery (e.g., neurological deficit scales) are not necessarily adequate. Indeed, single tests do not reflect the complexity of functional impairment and may not accurately predict neuroprotection (Corbett and Nurse, 1998) . Second, cell death is a complex process that can be postponed well beyond the expected maturation period. This delay may occur from use of a milder insult Du et al., 1996) or the use of a protective treatment Valtysson et al., 1994) , including TH (Colbourne and Corbett, 1995; Dietrich et al., 1993) . Thus, protection observed at early survival times (e.g., 48 h for focal ischemia, 7 days for global ischemia) may not be maintained later (e.g., 30 days). Third, animal models should be chosen to reflect the clinical condition of interest, and multiple models should be used as none are perfect. Fourth, it is important to take into account co-morbidities (e.g., age, hypertension). Finally, dose-response studies should be conducted, and for TH, this means varying, for example, the depth and duration of cooling, the intervention delay, and the re-warming rate. All of these factors interact to determine efficacy.
In addition to these concerns, animal studies of TH must also use appropriate methods to measure temperature. While the brain is the region of interest, most studies rely upon core temperature measurements, which are usually estimated by sampling rectal temperature because it is easier and less expensive. In rodents, core or rectal temperatures usually predict brain temperature reasonably well (DeBow and Colbourne, 2003) . However, during ischemia and anesthesia these can dissociate (Busto et al., 1987) . Furthermore, rectal temperature measurements cause stress-induced fever in awake rodents (DeBow and Colbourne, 2003) . With this method, it is also difficult to obtain enough readings in the post-stroke period to accurately control temperature. Implanted telemetry probes circumvent these problems, and allow for the repeated and precise sampling of body or brain temperature without causing undue stress (DeBow and Colbourne, 2003) . This is especially important when prolonged TH is used in conscious animals. A list of recommendations for temperature measurement in rodents is provided in Table 1, whereas Table 2 provides recommendations for temperature control in rodents.
The method of cooling is of great concern. In most cases, TH is induced systemically, and in a few cases selective brain cooling is used. In large animals (e.g., pig) these methods better mimic clinical procedures (e.g., cooling blankets and anesthesia). Similar methods have been used to induce brief TH (e.g., <12 h) in rodents. However, it is not feasible and safe to induce prolonged TH (e.g., >12 h) under anesthesia in rodents. Thus, for this, conscious animals are cooled via exposure techniques, such as with fans and water spray (DeBow and Colbourne, 2003) , the use of a cold room (Yanamoto et al., 2001) , or administration of some chemical such as H 2 S gas (Florian et al., 2008) . Several methods exist to selectively cool the brain. For instance, we recently developed a cooling method that can induce mild TH in one hemisphere, via an extra-cranial cooling coil, while the remainder of the brain and body remain normothermic . With this method, cooling can be maintained for days in conscious, mobile rodents. Regardless of the method used in rodents (Table 3) , it is important to remember there are always limitations, including important differences from the clinical use of TH.
Global Cerebral Ischemia
Mild TH reduces mortality and improves functional recovery after cardiac arrest (ventricular fibrillation) in patients (Bernard et al., 2002; The Hypothermia After Cardiac Arrest Study Group, 2002) as was predicted by numerous animal studies (Colbourne et al., 1997; Dietrich et al., 1996) . These clinical studies show that cooling to approximately 338C for Compliance should be stated in the paper. 2. Sufficient details of temperature measurement should be provided in the Methods section of papers. This would include information on the device (e.g., model) and procedural details (e.g., insertion depth into the rectum, duration of temperature measurement, sampling frequency). 3. When brain temperature is not measured, the relationship of the sampled temperature to brain temperature should be clearly shown, or at the very least, one should cite published work that demonstrates this relationship using similar techniques in that model. 4. Temperature should be repeatedly measured and recorded during and after surgery. A minimum of one day of recording is recommended following brain injury, longer in some circumstances. 5. Continuous temperature measurement and control is recommended during surgery. Temperature should be recorded at least every 2 h thereafter, but more frequently if temperature control is used. 6. Telemetry probes are strongly recommended for sampling temperature in conscious rodents owing to the ability to repeatedly sample temperature without the undue stress caused by non-telemetry systems (e.g., rectal temperature sampling). We recommend sampling temperature at least every 30 min with telemetry systems in conscious rodents, but more frequently if temperature is regulated.
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12-24 h improves outcome, but they did not identify the optimal treatment protocols needed to maximize efficacy while minimizing risk of side effects. Indeed, none of the clinical trials have systematically compared treatment protocols. Thus, at this time there are several important unresolved issues. First, there is considerable interest in finding more effective and safer ways to induce TH. Second, the optimal treatment parameters (e.g., duration and depth of cooling, rewarming rate) have not been established. Third, the conditions under which TH improves outcome are not known (e.g., cause of the arrest, longer intervention delays) and dependent upon improving treatment protocols. Efforts to improve systemic cooling methods have resulted in more precise control and a more rapid induction of TH. Better control improves patient safety and should improve efficacy. A more rapid induction of TH, such as by administering intravenous cold saline (Polderman et al., 2005) and endovascular catheter cooling devices , should appreciably improve outcome. Indeed, numerous animal studies (Table 4) show that TH provides greater cerebral protection when initiated sooner than later (Busto et al., 1989; Colbourne and Corbett, 1995; Kuboyama et al., 1993) . The development of selective brain cooling techniques (Wagner and Zuccarello, 2005) may also improve outcome after cardiac arrest; although, they are not expected to replace systemic TH because of the need to protect the whole body, not just the brain, from cardiac arrest. Nonetheless, it is possible that the brain will be cooled beyond that achieved for the body in order to maximize brain protection while minimizing systemic complications.
Few expect TH to protect against all global ischemic insults (e.g., causes of cardiac arrest), or in all situations (e.g., long intervention delays). Improvements can be made, however, by tailoring the TH protocol to each insult type and situation. For instance, 12 h of mild TH markedly reduces hippocampal CA1 sector cell death after 3 min of forebrain ischemia in gerbil, whereas considerably less protection is observed after a 5-min insult, unless cooling is maintained for 24 h (Colbourne and . Thus, more severe insults require longer cooling. Similarly, longer cooling may be needed when greater intervention delays occur. For example, 24 h of TH has a therapeutic window of about 4 h after a 5-min insult in gerbil (Colbourne and Corbett, 1995) , whereas 48 h of cooling has a therapeutic window of more than 12 h . Finally, whereas prolonged cooling results in persistent CA1 protection in rats and gerbils (Colbourne and Corbett, 1995) , brief TH (e.g., 3 h) only transiently rescues these neurons from forebrain ischemia (Dietrich et al., 1993) , unless it is combined with another neuroprotectant (Dietrich et al., 1995) . Importantly, postschemic TH also improves histological and functional outcome in cardiac arrest models in rodents (Hickey et al., 2000; Hicks et al., 2000; Logue et al., 2007) and dogs (Leonov et al., 1990; Weinrauch et al., 1992) , and, as in the rodent forebrain ischemia models, various parameters have been evaluated with somewhat similar findings compared to rodent studies.
From examining single studies and a comparison among studies, it is clear that protection depends upon insult severity, intervention delay, the depth and duration of cooling, and does not obviate the need for frequent temperature measurement. 4. Heating devices (e.g., lamps) must be positioned such that they provide uniform heating and do not cause burns. 5. The use of infrared lamps, and perhaps other devices, may overheat the brain when core temperature is solely measured.
Note that the recommendations in Table 1 are even more important when temperature is regulated. Table 3 lists various methods to induce therapeutic hypothermia in rodents. (Wei et al., 2008) The selected publications either describe the technique or use the method in a stroke model. These methods have not been compared with respect to efficiency and safety. the re-warming rate. Despite this knowledge, it is very difficult to identify optimal treatment parameters for treating global ischemia because few studies have systematically evaluated multiple TH parameters, and a comparison among studies is often confounded by different methodologies (e.g., model, method of cooling, endpoints). Thus, for example, one cannot find unequivocal evidence to identify the most effective level of TH, which is obviously constrained by cooling method and the occurrence of side-effects. Accordingly, because systemic cooling to 358C is somewhat safer than cooling to 338C (Schubert, 1995) , it makes sense to only cool to 358C if both protocols provide equivalent protection, as some argue (Logue et al., 2007) . However, a global ischemia study in gerbil found that 328C cooling provided somewhat better histological protection compared to 348C (Colbourne and Corbett, 1995) . Both studies used comparable treatment durations and cooling methods. The cause of this discrepancy may have resulted from using, for example, different species, insult severities, survival times, outcome measures, methods of measuring temperature, and re-warming rates. For example, 33-358C might provide equivalent protection at short survival times, but a difference could emerge at longer survival times. Similarly, differences in efficacy might occur when treating more severe injury or when cooling is delayed. In those cases, deeper and longer cooling may be necessary. Finally, given the possibility of using selective brain cooling or the combination of systemic cooling with further brain cooling, it would be prudent to re-evaluate whether moderate selective brain TH (e.g., 288C) more effectively reduces brain injury than the milder cooling (e.g., 338C) currently used in most clinical and animal studies. In such an experiment it would be necessary to keep other factors in mind (e.g., rewarming rate, duration of cooling).
At this time we are strongly recommending the evaluation of multiple TH parameters in a single study or a series of studies using identical conditions. Indeed, it is somewhat surprising that such studies are rare. Perhaps this is due to the onerous and difficult nature of conducting parametric studies, and that they appear less interesting than examining mechanisms of action. However, the known and suspected interac- Declining CA1 sector protection with increasing delays (4-day survival).
No protection after a 3-h delay (Carroll and Beek, 1992) 5 h of mild TH (*338C) induced at delays of 2-36 h after forebrain ischemia in rat
Reduced CA1 sector injury with up to 12-h delayed TH, whereas striatal injury was reduced only with the 2-h delayed treatment (Coimbra and Wieloch, 1994) 24 h of mild TH (328C) induced 1 or 4 h after forebrain ischemia in gerbils Significant behavioral and CA1 sector protection out to 6 months with both treatments, but considerably better protection with the earlier intervention (Colbourne and Corbett, 1995) Over 2 days of mild TH (32-348C) was induced 1, 6, or 12 h after forebrain ischemia in gerbils
Declining protection with intervention delay, but significant CA1 sector protection was observed in all cases. Survival times were 4, 14, and 60 days, and the more delayed interventions resulted in some loss of protection over time TH, therapeutic hypothermia.
tions among treatment parameters necessitates that this work be done.
Focal Ischemia
In light of the clinical success of TH in cardiac arrest patients, there is great hope that TH will reduce morbidity and mortality following ischemic stroke beyond that expected with preventing fever, which commonly occurs (Ginsberg and Busto, 1998) . Several small clinical trials (Kammersgaard et al., 2000; Schwab et al., 1998 Schwab et al., , 2001 show that TH is safe for stroke patients, but such studies have not been powered to determine efficacy. Indeed, the parameters that will likely critically determine efficacy, such as depth and duration of cooling, intervention delay, and re-warming rate have not been systematically varied in clinical studies. One cannot assume that TH protocols effective in global ischemia will be equally effective for stroke. Thus, it makes sense to identify optimal TH parameters in animal studies prior to initiating large and costly clinical trials.
Collectively, there is no doubt that TH can reduce focal ischemic injury in animals (Table 5) . Indeed, numerous preclinical studies show that TH initiated during ischemia or after a delay can reduce infarct size and mitigate functional impairment as summarized in a recent meta-analysis (van der Worp et al., 2007) . Importantly, TH also provides lasting protection, at least when cooling is prolonged (e.g., >1 day) Corbett et al., 2000; Florian et al., 2008; Yanamoto et al., 2001) . While several studies have systematically varied cooling parameters to identify optimal treatments, these have tended to use brief cooling, such as <6 h (Kollmar et al., 2007; Maier et al., 1998) . Recently, we compared 12, 24, and 48 h of systemic TH (338C) induced 1 h after onset of a permanent middle cerebral artery occlusion (pMCAO) in rats (Clark et al., 2009) . Significantly greater neuroprotection and functional improvement at 7 days was observed with 24 and 48 h of cooling compared to the 12 hr duration. Thus, these findings support the use of prolonged periods of TH whenever possible.
The depth of TH will also profoundly affect treatment efficacy. Given that moderate to severe TH causes adverse side effects, such as infection and cardiovascular complications (Schubert, 1995) , many animal and clinical studies use mild TH. A recent comparison of brief (4 h) TH protocols (range of 32-378C) following transient MCAO (tMCAO) revealed that TH at 348C provided the greatest histological and functional benefit, whereas 328C was ineffective (Kollmar et al., 2007) . This contrasts other findings that 328C is neuroprotective and better than milder TH after focal ischemia (Maier et al., 1998) . Importantly, these studies used relatively brief durations of TH, and it is possible that the optimal depth of cooling will depend on and interact with other parameters, including the duration of TH, intervention delay, the method of cooling, and rate of re-warming.
A treatment's therapeutic window is of critical importance to clinical success given the unavoidable delays in patient treatment. Several studies have shown that TH can be delayed following the onset of tMCAO or pMCAO (Baker et al., 1992; Clark et al., 2009; Kader et al., 1992; Maier et al., 2001; Ohta et al., 2007; Xue et al., 1992; Yanamoto et al., 1996) and still provide benefit, although the therapeutic window does not always seem that wide. We suspect that with more effective Infarct size was significantly reduced out to a 5-day survival time with the best protection found in the 348C treatment (Kollmar et al., 2007) Duration 1-4 h of TH (*338C) induced immediately after onset of a 3-h MCAO in rat Significant reduction in infarct size with 3 and 4 h of TH only (3-day survival) (Markarian et al., 1996) 1 vs. 21 h of TH (33-368C) induced upon reperfusion from a 3-h MCAO in rat (vs. hyperthermic controls)
Histological protection was observed at 1 and 2 days with 21, but not the 1-h period of delayed TH (Yanamoto et al., 1996) 12 vs. 24 vs. 48 h of TH (338C) induced 1 h after onset of pMCAO in rat 24 and 48 h of TH were superior to 12 h in reducing infarct size and improving behavioral recovery out to 7 days post-stroke (Clark et al., in press) Delay 3 h of mild TH (*338C) induced from 0-45 min after onset of transient MCAO, which lasted 3 h Significant reduction in infarct size (3-day survival) with up to a 30-min delay (Markarian et al., 1996) *2 days of mild TH (*358C) initiated 0, 2, 4, or 6 h after onset of reperfusion in rats subjected to a 2-hr MCAO Declining histological protection at a 2-day survival with intervention delays out to 4-h post-stroke. (Ohta et al., 2007) MCAO, middle cerebral artery occlusion; pMCAO, permanent MCAO.
treatment protocols, notably protracted TH (Ohta et al., 2007) , the therapeutic window will be sufficiently wide to allow effective clinical use of TH. In summary, there is growing evidence that TH will be efficacious in focal ischemia, as it is for global ischemia. However, it is essential that the optimal TH parameters be defined for focal ischemia. This includes the optimal duration and depth of TH, intervention delay, potential side effects, as well as the conditions in which TH is used (i.e., tMCAO vs. pMCAO). It is clear that experimental studies must methodically assess these parameters prior to the use of TH in stroke patients.
Intracerebral Hemorrhage
Intracerebral hemorrhage is a devastating stroke that accounts for about 15% of all strokes. Hemorrhaging also follows TBI and focal ischemia; the latter occurs spontaneously and from rt-PA-induced hemorrhagic transformation (Khatri et al., 2007) . Relative to ischemic stroke, much less effort has been directed at determining the pathophysiology of ICH and at identifying effective treatments, which includes the study of TH. Indeed, only one small clinical study assessed the effects of prolonged brain TH (68C for 48 h) in 20 ICH patients (Feng et al., 2002) . They reported that TH reduced edema and functional deficits, and was not associated with significant negative side effects. Clearly, further study is needed to determine efficacy for ICH. Also, regardless of whether TH helps those presenting with an ICH, its effects on hemorrhaging need to be determined given the possibility of hemorrhagic transformation after ischemic stroke, which is likely to be treated with TH.
In rodents, an ICH is produced by either infusing autologous blood (Bullock et al., 1984) or bacterial collagenase to cause bleeding (Rosenberg et al., 1990 ). The blood model mimics a single large bleed that occurs in most ICH patients, whereas collagenase disrupts the basal lamina causing slow bleeding over approximately 6 h. This model may best represent the ongoing bleeding experienced by approximately one third of ICH patients. The time course of injury (Del Bigio et al., 1996; Felberg et al., 2002) and functional deficits (Hua et al., 2002; have been well characterized and compared in both models, which are significantly different (MacLellan et al., 2008) . More simplified models are also used (e.g., intra-parenchymal injections of iron or thrombin).
Several rodent studies show that prolonged TH reduces inflammation, edema and blood-brain barrier (BBB) disruption after intra-striatal thrombin injections (Kawai et al., 2001) , and in the whole blood model (Dai et al., 2006; Fingas et al., 2007; Kawanishi, 2003; . A similar effect was found with profound local TH in pigs subjected to an ICH (Wagner et al., 2006) . Despite these reproducible effects, functional and histological benefits are not consistently found (Fingas et al., 2007; MacLellan et al., 2004 ; although, this appears to depend upon the model, insult severity, and time of treatment. For instance, prolonged TH (33-358C for 48 h) failed to reduce lesion size when started soon after collagenase-induced ICH, whereas 12-h delayed treatment was effective (MacLellan et al., 2004) . The early treatment aggravated bleeding, perhaps because of a mild increase in blood pressure caused by systemic cooling (MacLellan et al., 2004) or a cold-induced coagulopathy (Schubert, 1995) . Bleeding occurs for hr following collagenase infusion, unlike in the whole blood model (MacLellan et al., 2008) . Thus, the aggravated bleeding in the early phase of ICH may have counteracted the beneficial effects of prolonged TH, resulting in no net protection. Conversely, 12-h delayed cooling would not aggravate bleeding because it would have ceased by that onset time. These findings suggest that the therapeutic time window for ICH may not mirror that of cerebral ischemia. Furthermore, it raises concerns of worsened outcome if focal ischemia patients experience hemorrhagic transformation during TH.
We tested the hypothesis that a similar TH protocol would improve outcome when initiated soon after whole-blood infusion in rat striatum . This was based upon the premise that bleeding would not be aggravated by TH, which was confirmed, and therefore, TH was expected to reduce injury. Cooling significantly lessened inflammation, BBB disruption and edema, but did not notably affect behavioral recovery or brain injury. A follow-up study using 4 days of selective brain TH (*328C) induced 1 or 12 h after blood infusion in rat striatum obtained similar results (Fingas et al., 2007) . However, this study used rapid re-warming, which may negate protection. It should be noted that no study has examined re-warming rates following selective brain cooling, and it is possible, that re-warming rate is less important following selective brain TH than after systemic TH. Our studies that used systemic cooling after ICH (MacLellan et al., 2004 ) used a stepwise, slow re-warming protocol after prolonged TH.
In contrast to cerebral ischemia studies, TH does not consistently improve behavioral recovery or lessen brain injury in most ICH studies, despite the use of TH protocols found highly effective against ischemia. There are several possible explanations that warrant consideration. First, TH may simply be an ineffective or weak cytoprotectant for ICH. Furthermore, the reductions in edema, BBB disruption, and inflammation are unimportant or below the threshold for affecting functional and histological outcome in rodent ICH models. Second, animal models of ICH may not be truly suitable for assessing neuroprotection, as indicated by the many drug studies that fail to lessen lesion volume after ICH. Of course, whether significant neuroprotection in patients, independent of affecting hematoma size, is possible or not remains to be shown. Third, alternative TH protocols (e.g., deeper and longer treatment) may improve outcome in these models and clinically. Until clearly effective protocols are identified, the data do not support the study of TH for ICH patients at this time.
Use of TH may not be well supported, but many would argue that fever should at least be prevented. Indeed, ischemic stroke is so highly sensitive to hyperthermia and fever (Ginsberg and Busto, 1998) that it is tempting to assume that ICH is similarly aggravated by fever, which commonly occurs in ICH patients (Schwarz et al., 2000) . However, the relationship between fever and outcome after ICH is unclear due to the small number of investigations and conflicting results. For instance, several studies reported that fever does not independently predict mortality after ICH (Boysen and Christensen, 2001; Szczudlik et al., 2002) , whereas others argue that fever independently worsens outcome after ICH (Leira et al., 2004; Schwarz et al., 2000) . There is only one preclinical study 318 MACLELLAN ET AL.
that assessed the effects of induced hyperthermia on outcome following collagenase-induced ICH in rats. This study reported that hyperthermia (e.g., 408C for 3 h) did not worsen injury or functional impairment . These results do not exclude the possibility that fever from infection, or greater and more protracted hyperthermia could worsen outcome. Further study is needed. In summary, TH provides several benefits for ICH (e.g., reduced BBB disruption and edema) that should theoretically reduce mortality and morbidity in patients. However, determining whether some TH protocol is reproducibly neuroprotective after ICH awaits further study. In this regard, it is important to systematically vary treatment protocols and to use additional animal models that better mimic the pathology of human ICH (ICH Recommendations, 2005) . In this regard, the risk of prolonging bleed time must be considered. Hopefully, this might be either treated (e.g., rFVIIa), or avoided by careful patient selection (e.g., those at low risk for re-bleeding) or through the use of delayed TH.
Subarachnoid Hemorrhage
Subarachnoid hemorrhage shares many pathophysiological features with ischemia and ICH (Thome et al., 2005) . Furthermore, ischemia is often observed following SAH due to cerebral vasospasm and elevated intracranial pressure. For these reasons, treatments such as TH that reduce ischemic injury and neurotoxicity should benefit SAH patients.
As with ischemic stroke, fever often follows SAH (Fernandez et al., 2007; Oliveira-Filho et al., 2001 ). For example, Fernandez et al. (2007) found that 72% of their patients were febrile, and with every 18C increase in temperature there was an eightfold increased risk of death and a threefold increased risk of severe disability. The development of a fever is not notably related to minor infections (Oliveira-Filho et al., 2001 ), but rather to secondary brain injury, such as brainstem herniation and vasospasm (Fernandez et al., 2007) . This suggests that injury to central thermoregulatory centers may be the primary cause of altered thermoregulation. Regardless, these findings imply that TH, or at least prevention of fever (Badjatia et al., 2004) , might improve outcome after SAH.
Treatment of SAH with TH is more complicated than following cerebral ischemia in that SAH patients may either be cooled soon after SAH or at a delayed time during or after aneurysm repair. Indeed, brief TH has been used intraoperatively during aneurism repair (Anderson et al., 2006; Hindman et al., 1999; Karibe et al., 2000; Samra et al., 2007; Todd et al., 2005) . Although shown to be safe (i.e., does not increase the risk of infection or duration of hospitalization), TH does not benefit SAH patients. For instance, brief TH does not improve neurological outcome measured out to 15 months after surgery (Anderson et al., 2006; Samra et al., 2007; Todd et al., 2005) . Importantly, in these studies TH was maintained for only a few hours, and patients were rewarmed quickly after surgery. Thus, alternative TH treatments, such as prolonged TH, slower re-warming, and earlier usage, might benefit SAH as it has for cardiac arrest patients. In this regard, several studies have used prolonged systemic TH (e.g., 338C out to 2 weeks in duration) after aneurysm surgery (Gasser et al., 2003; Nakamura et al., 2002) . Although suggesting benefit, randomized trials are needed to prove this, and the risk of side effects needs to be further minimized.
There are several rodent models of SAH used to evaluate the efficacy and mechanisms of action of putative treatments (Prunell et al., 2003) . As with other types of brain injury, each SAH model has advantages and limitations. The intraluminal perforation model results in mortality rates that most accurately reflect the mortality in SAH patients (Bederson et al., 1995) , and is preferred by many researchers because a craniotomy is not produced. However, this model does not result in significant and persistent functional impairments (Thal et al., 2008; Silasi and Colbourne, in press ), making it difficult to gauge neuroprotective efficacy beyond that which affects survival. The direct injection of blood into the cavernous cisterns may be better suited for studying the pathophysiology of SAH, such as vasospasm and molecular signaling cascades (Prunell et al., 2003) .
Unfortunately, very few preclinical studies have evaluated whether TH reduces mortality and functional deficits in animal models of SAH. Although the optimal cooling parameters have not been defined, several investigators have assessed mechanisms of TH protection. For example, TH (328C for 2 h) reduced brain water content when it was induced immediately or delayed for 1 h after SAH, which was produced by injecting blood into the cistern magna (Piepgras et al., 2001) . Another study demonstrated that intra-operative TH decreased the early expression of genes associated with cellular stress, such as hsp 70 and c-jun following SAH in rats caused by endovascular perforation (Kawamura et al., 2000) . Finally, brief TH (328C) induced prior to or immediately upon blood injection into the cisterna magna of rats reduced the hypoperfusion and metabolic derangements, such as the accumulation of glutamate, observed soon after SAH (Schubert et al., 2008) .
In summary, brief TH does not improve outcome when applied for aneurysm repair; yet, it remains possible that prolonged TH might improve outcome after SAH, especially in those cases with vasospasm-induced ischemia. The development of effective TH treatments for SAH patients requires that several important issues be addressed (e.g., optimal depth and duration of TH). More appropriate animal models are needed in this regard (e.g., allowing for long-term assessment).
Conclusion
Animal studies conclusively show that TH is neuroprotective against focal and global cerebral ischemia. Conversely, convincing experimental evidence that TH improves survival and lessens functional impairment after either ICH or SAH is lacking. Clinically, TH reduces mortality and disability after cardiac arrest. The latter suggests a neuroprotective effect, but the true extent of this has yet to be shown. Cooling has also been repeatedly examined in ischemic and hemorrhagic stroke patients, but these studies were only powered to determine feasibility and safety, not efficacy.
From animal studies it is clear that protection depends upon: insult type and severity, intervention delay, and several treatment parameters (e.g., depth and duration of cooling, rewarming rate). However, despite decades of research, answers to even the fundamental questions, such as the optimal depth and duration of TH, are difficult to find. Certainly these questions have been addressed in numerous papers, but in most cases the studies have significant limitations (e.g., use of short survival times). Notably, the full range of a treatment parameter (e.g., duration of TH) was either not used, or the interaction of that parameter with others was not considered. For example, 4 and 6 h of TH may be equally effective in reducing infarct size leading one to conclude that 4 hr is the optimal duration of cooling, when both are likely far inferior to much longer durations of TH (e.g., 24 h). Likewise, 24 h of TH may be optimal when initiated soon after mild ischemia, but not when started later or after more severe ischemia. As another example, earlier intervention is clearly superior to delayed treatment after cerebral ischemia, but this may not hold for hemorrhagic stroke where bleeding may be aggravated by early TH.
We strongly recommend that further animal work be completed prior to and concurrently with clinical studies. These animal studies should adhere to the STAIR recommendations (STAIR, 1999) , such as the use of behavioral tests and longer survival times, and seek to identify optimal treatment protocols for each insult type and situation in an effort to maximize the likelihood of clinical success. We caution that a comparison among studies, as done in numerous reviews including this one, is problematic owing to numerous differences among those experiments (e.g., model, insult severity, method of temperature measurement and control, TH protocols used). For this reason, we are urging investigators to consider the recommendations put forth in Tables 1 and 2 , which should aid in comparing among studies and eventually translating TH to the clinic. Additionally, use of standardized procedures (e.g., stroke model, cooling method) and their dissemination in detailed form (e.g., published protocols or posting them on one's laboratory web site) should improve consistency within the field. Finally, we urge investigators to use clinically relevant treatment protocols in mechanistic studies. Notably, most such studies have used brief TH, or cooling instituted very quickly after ischemia followed by rapid re-warming. Not only is brief TH sub-optimal, but the mechanisms by which early and brief TH reduces injury are likely to differ from the protection afforded by more delayed and protracted TH.
In summary, we expect that several days or more of mild to moderate TH will improve outcome after ischemic stroke, and it is possible that similar treatments will help in selected cases of ICH and SAH. However, further animal study is needed to improve treatment protocols for planning clinical trials and implementing TH in the clinic. As well, the interaction of TH with other therapies, such as rt-PA for ischemic stroke and potentially rFVIIa for hemorrhagic stroke, needs to be clearly evaluated. Until then, clinical studies risk using ineffective or harmful TH protocols and perhaps erroneously concluding that TH is useless.
